Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 70500
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Mapk1
Name: mitogen activated protein kinase 1
Acc ID: CHEBI:78741
Term: oxidopamine
Definition: A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Chemical ID: MESH:D016627
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Mapk1increases phosphorylationEXP 6480464CTDOxidopamine results in increased phosphorylation of MAPK1 proteinPMID:22016808
Mapk1multiple interactionsEXP 6480464CTDOxidopamine results in increased phosphorylation of and results in increased activity of MAPK1 proteinPMID:21397656
Mapk1affects phosphorylationISOMapk1 (Mus musculus)6480464CTDOxidopamine affects the phosphorylation of MAPK1 proteinPMID:33571554
Mapk1increases phosphorylationISOMAPK1 (Homo sapiens)6480464CTDOxidopamine results in increased phosphorylation of MAPK1 proteinPMID:24997245 PMID:31176653 PMID:33486071
Mapk1increases phosphorylationISOMapk1 (Mus musculus)6480464CTDOxidopamine results in increased phosphorylation of MAPK1 proteinPMID:22016808 PMID:23518299
Mapk1multiple interactionsISOMAPK1 (Homo sapiens)6480464CTD2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]PMID:24997245 PMID:33486071
Mapk1multiple interactionsISOMapk1 (Mus musculus)6480464CTD2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK1 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]PMID:16139809 PMID:17596448 PMID:19187092 PMID:19520364 PMID:23518299 PMID:33571554
Go Back to source page   Continue to Ontology report